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Abstract
Background: MicroRNAs (miRNAs) have been shown to anticipate great cancer diagnostic potential. Recently, circulating
miRNAs have been reported as promising biomarkers for various pathologic conditions. The objective of this study was to
investigate the potential of serum miRNAs as novel biomarkers for hepatocellular carcinoma (HCC).
Methodology/Principal Findings: This study was divided into four phases: (I) Ten candidate serum miRNAs were detected
by using real-time RT-PCR, corresponding 10 HCC patients with chronic hepatitis B virus (HBV) infection and 10 age- and
sex-matched healthy subjects. (II) Marker validation by real-time RT-PCR on HBV patients with (n=48) or without HCC
(n=48), and healthy subjects (n=24). (III) Marker detection by real-time RT-PCR in sera from another 14 HCC patients before
and 1 month after surgical resection. (IV) We examined the correlation between the expressions of candidate serum miRNAs
with clinical parameters of HCC patients. Although miR-222, miR-223 or miR-21 were significantly up- or down-regulated
between HCC patients and healthy controls, no significant difference was observed in the levels of these miRNAs between
HBV patients without and with HCC. MiR-122 in serum was significantly higher in HCC patients than healthy controls
(p,0.001). More importantly, it was found that the levels of miR-122 were significantly reduced in the post-operative serum
samples when compared to the pre-operative samples. Although serum miR-122 was also elevated in HBV patients with
HCC comparing with those without HCC, the difference was at the border line (p=0.043).
Conclusions/Significance: Our results suggest that serum miR-122 might serve as a novel and potential noninvasive
biomarker for detection of HCC in healthy subjects, moreover, it might serve as a novel biomarker for liver injury but not
specifically for detection of HCC in chronic HBV infection patients.
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Introduction
Hepatocellular carcinoma (HCC) accounts for 90% of primary
liver cancers and it represents the third most common cause of
death from cancer worldwide, with an increasing incidence
expected in the next decades [1]. The major risk factors are
chronic viral hepatitis B and C (HBV, HCV), alcohol abuse,
primary biliary cirrhosis, xenobiotics, diabetes, non-alcoholic fatty
liver disease and genetic disorders like haemochromatosis and a1-
antitrypsin deficiency [2,3]. In China, HCC is the second highest
cancer killer since the 1990s [4] and HBV infection is highly
endemic. The high mortality rate is due to its detection at late stage
with limited therapeutic options. Indeed, the clinical heterogeneity
of HCC and the lack of good diagnostic markers and treatment
strategies have rendered the disease a major challenge.
The search for biomarkers for the diagnosis of diseases has become
a rapidly growing area of clinical research. Ideally, biomarkersshould
be easily accessible such that they can be sampled non-invasively.
Therefore biomarkers that can be sampled from body fluids, such as
serum or urine, are particularly desirable. Circulating nucleic acids
(CNAs) are extracellular nucleic acids found in cell-free serum,
plasma and other body fluids from healthy subjects as well as from
patients. The ability to detect and quantitate specific DNA and RNA
sequences has opened up the possibility of diagnosis and monitoring
of diseases, especially in the field of cancer [5]. Furthermore, in some
recent studies it has been suggested a kind of non-coding RNA—
microRNA (miRNA), also exist in cell-free serum and plasma,
highlighting the field of using CNAs to diagnose cancer.
MiRNAs are a group of tiny RNAs with a fundamental role in
the regulation of gene expression. Aberrant expression of several
miRNAs was found to be involved in a large variety of neoplasms
[6], including HCC [7–12]. A relevant and important feature of
miRNAs is their remarkable stability. They are known to be well
preserved in tissue samples even after years of formalin-fixation
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quantified in such specimens [13]. Investigation of cancer-specific
miRNAs in the circulation is an emerging and exciting field of
study. One of the first studies measuring miRNA levels in serum
was reported by Lawrie et al. [14], who showed that sera levels of
miR-21 were associated with relapse-free survival in patients with
diffuse large B-cell lymphoma. Subsequently, circulating miRNAs
have been postulated as novel biomarkers for cancer, and other
disease processes [15–27]. To date, there have been no
systematical reports on the role of circulating miRNAs in HCC,
and it is not fully understood whether serum miRNAs have a
clinicopathological influence in HCC. We hypothesized that levels
of specific cancer-associated miRNAs in circulation would differ
between HCC patients and chronic HBV infection patients
without HCC or healthy individuals. If this hypothesis held truth,
it would signify a major breakthrough in HCC management,
bringing us ever closer to finding a novel, sensitive, and
noninvasive biomarker for this common disease.
The primary aim of this study was to investigate whether
cancer-specific miRNAs are detectable and altered in serum of
HCC patients compared with age- and sex-matched disease and
healthy controls. We also collected serum samples from HCC
patients before and after the tumor resection, and these samples
were used to determine whether those up-regulated markers in
cancer serum were reduced after the tumor resection. Finally, a
potential relationship between circulating miRNAs levels and
existing clinicopathological features of HCC, such as tumor
number, size, growth phase, stage, Child-pugh grade and overall
survival, was investigated.
Results
Patient Characteristics
A total of 152 participants including 70 HBV-positive HCC
patients, 48 chronic HBV infection patients without HCC, and 34
normal subjects were recruited into this study (Table 1). There
were no significant differences of age (t-test) and sex (Pearson x
2
test) between cases and controls. In addition, the HCC group and
the other two controls groups had statistically different laboratory
results for ALB, T-Bil and ALT (p,0.001).
With regard to clinicopathologic characteristics of HCC
patients, single tumor was found in 48 patients (68.6%), tumor
diameter was ,5 cm in 17 patients (24.3%), 51 patients were also
with hepatic cirrhosis. The histologic grade of HCC was grade I–II
in 14 cases, grade III–IV in 51 cases. Tumor stage was obtained
according to the TNM criteria, 8, 36 and 20 patients was in stage
I, II, III, and only 6 patients was in stage IV. According to the
Child classification [28], 59, 8 and 3 patients was with mild (grade
A), moderate (grade B) and severe (grade C) liver damage,
respectively. All HCC patients had completed follow-up. Forty-
one patients who survived more than 20 months (average, 25.65
months; range, 21.3 to 31.3 months) on the last follow-up were
classified as the longer-survival group, whereas the rest twenty-
nine patients who had survival times less than 20 months (average,
10.93 months; range, 5.3 to 19.2 months) were classified as the
shorter-survival group.
Identification of HCC-associated MiRNAs in Serum
The goal of the present study was to explore the potential use of
serum miRNAs as biomarkers for HCC. In this marker discovery
phase, a panel of 10 cancer associated miRNAs was chosen on the
basis of their reported relevance to HCC [7–12] and detected by
RT-qPCR among 10 HCC patients and 10 healthy subjects. Using
miR-16 as normalization control, 3 significantly up-regulated
miRNAs (miR-122, miR-222 and miR-223) and 1 significantly
down-regulated miRNA (miR-21) in serum in HCC patients were
identified (Figure 1 A–,B, C, D), while expression levels of miR-
221 and miR-301 in serum were non-significantly higher in HCC
patients than in healthy subjects (Figure 1 E, F). As for miR-224,
let-7a and miR-199a, the detection rates were ,50% in serum
samples by RT-qPCR, thus, these miRNAs were not chosen in
further analytic studies.
Marker Selection and Validation in Serum Samples
To validate the 4 putative markers identified from the marker
discovery phase, RT-qPCR assays were developed to quantify
Table 1. Summary of clinical details of subjects used for
miRNA analysis.
Healthy
control
(n=34)
HBV patients
without HCC
(n=48)
HBV patients
with HCC
(n=70)
Age, median, y 38 45 49
Men, n (%) 24 (70.8) 37 (77.1) 55 (78.6)
Laboratory values
mean (SD)
Total bilirubin
b, mmol/L 14.1 (5.3) 14.9 (6.2) 19.2 (10.3)
Albumin
a, g/L 48.6 (2.9) 47.3 (3.5) 40.1 (3.9)
Alanine aminotransferase
b,
U/L
20.3 (12.2) 26.2 (10.6) 116.6 (257.6)
Tumor number
(n=70) n (%)
Single 48 (68.6)
Multiple 22 (31.4)
Tumor size
(n=70) n (%)
,5c m 1 7( 2 4 . 3 )
$5c m 5 3( 7 5 . 7 )
Tumor grade
(n=65) n (%)
I and II 14 (21.5)
III and IV 51 (78.5)
Tumor stage
(n=70) n (%)*
I 8 (11.4)
II 36 (51.4)
III 20 (28.6)
IV 6 (8.6)
Hepatic cirrhosis status
(n=68) n (%)
Positive 51 (75.0)
Negative 17 (25.0)
Child-pugh grade
(n=70) n (%)
A5 9 ( 8 4 . 3 )
B 8 (11.4)
C 3 (4.3)
a, significant difference exists between three cohorts (p,0.001).
b, significant difference exists between HCC group and non-HCC groups
(p,0.001).
*Tumor stage was obtained according to the TNM criteria.
doi:10.1371/journal.pone.0028486.t001
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without HCC and 24 healthy subjects. Our data indicated that
expression levels of miR-122 in serum were significantly higher in
HCC patients than disease controls (p,0.05) or healthy controls
(p,0.001) (Figure 2 A). Although levels of miR-222 and miR-223
were also significantly elevated in HCC patients than in healthy
controls (p,0.05), no significant difference was observed for these
two miRNAs between HBV subjects with and without HCC
(p.0.05) (Figure 2 B, C). Interestingly, the levels of miR-223 in
serum of HBV patients without HCC were non-significantly
higher than those in patients with HCC. In addition, levels of
miR-21 were reduced in HCC patients than in healthy controls
(p,0.05), no significant difference was observed for miR-21 be-
tween HBV subjects with and without HCC (p.0.05) (Figure 2 D).
In order to prove circulating miR-122 in serum is of tumor
origin, its levels were measured in an independent set of 14 HCC
patients (before and one month after surgical removal of the
tumors). It was found that the levels of miR-122 were significantly
reduced in the post-operative serum samples when compared to
the pre-operative samples, reaching levels comparable with
healthy subjects (Figure 3).
The Diagnostic Value of MiR-122 for HCC
To evaluate whether serum miR-122 can be used as a potential
diagnostic marker for HCC, ROC curve analyses were performed.
It was revealed that serum miR-122 was a potential marker for
discriminating HCC patients from healthy controls with an AUC
(the areas under the ROC curve) of 0.869 (95% CI: 0.786–0.952)
(Figure 4 A). At the cut-off value of 0.475, the sensitivity and
specificity for this marker was 81.6% and 83.3%. However, the
AUC of serum miR-122 for discriminating HBV patients with
HCC from those without HCC was only 0.630 (95% CI: 0.516–
0.743) (Figure 4 B). At the cut-off value of 0.651, the sensitivity
and specificity for this marker were 77.6% and 57.8%.
Relationship of Circulating MiRNAs to Clinicopathological
Parameters
It was reported that some unique miRNA signatures were
associated with prognostic factors and disease progression in
several cancers. Therefore, we examined the correlation between
the expression of circulating miR-122, miR-222, miR-223 and
miR-21 with clinical parameters. No significant association was
found between the four miRNAs and tumor number, size, growth
phase, stage, Child-pugh grade and overall survival (p.0.05),
while the levels of miR-122 demonstrated an elevation trend in
patients with small tumor (p=0.055). In addition, large tumor
patients were found to have non-significantly higher levels, on
average, of serum miR-21 compared with those with small tumor
(p=0.051). A potential relationship between circulating miRNA
levels and status of liver cirrhosis, was also investigated, but no
statistically significant difference was identified for any of these
parameters.
Discussion
HCC represents an extremely poor prognostic cancer that
remains one of the most common and aggressive human
malignancies worldwide. The early diagnosis of HCC is of great
clinical desirable and the improved prognosis of HCC if the
patients could get surgical treatment early. Up to now, alpha-
fetoprotein (a-AFP) has mainly been used in clinic for diagnosis of
primary HCC; however, its sensitivity and specificity are not
satisfying [29], novel biomarkers for early HCC diagnosis are
greatly needed.
Results from recent studies revealed that circulating miRNAs
are potential diagnostic biomarkers and prognostic factors in
various kinds of diseases, especially in the field of cancer. The first
serum miRNA biomarker discovered was miR-21. Lawrie et al.
found that patients with diffuse large B cell lymphoma had high
serum levels of miR-21, which associated with increased relapse-
free survival [14]. Mitchell et al. demonstrated the presence of
circulating tumor-derived miRNAs in blood by using a mouse
prostate cancer xenograft model system and showed that
measurements obtained from plasma were strongly correlated
with those obtained from sera, suggesting that both serum and
plasma samples would be adequate for measuring specific miRNA
levels [16]. In another study, Chen et al. demonstrated that by
using serum directly or by extracting RNA from the serum they
could identify unique miRNA expression profiles for lung cancer,
colorectal cancer and diabetes patients compared with healthy
subjects [15]. Circulating miRNAs have also been postulated as
Figure 1. Expression levels of miRNAs in serum of HCC patients and healthy subjects. Levels of miR-122 (A), miR-222 (B), miR-223 (C), miR-
21 (D), miR-221 (E), and miR-301 (F) were measured in serum of HCC patients (n=10) and healthy subjects (n=10) by RT-qPCR. Using miR-16 as
normalization control, 3 significantly up-regulated miRNAs (miR-122, miR-222 and miR-223) and 1 significantly down-regulated miRNA (miR-21) in
serum in HCC patients were identified, while expression levels of miR-221 and miR-301 in serum were non-significantly higher in HCC patients than in
healthy subjects.
doi:10.1371/journal.pone.0028486.g001
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[19] and colorectal cancer [23,24]. Although the clinical
significance of these findings has not been elucidated in detail,
those findings demonstrated that circulating miRNAs could be
noninvasive diagnostic or prognostic markers for cancer.
In this study, we confirm that some miRNAs can be measured
from a relatively small amount of serum. In addition, as there is no
current consensus on the use of house-keeping miRNAs for RT-
qPCR analysis, based on previously published results [14,23] and
as recommended by the manufacturer (Applied Biosystems), we
used miR-16 levels for normalization. We found that the levels of
miR-122 in serum samples from HCC patients were significantly
higher than healthy subjects (p,0.001). Although serum miR-122
was also elevated in HBV patients with HCC comparing with
those without HCC, the difference was at the border line
(p=0.043). Serum miR-122 yielded an AUC of 0.869 (95% CI:
0.786–0.952) for discriminating HCC from healthy subjects and
only 0.630 (95% CI: 0.516–0.743) for discriminating HBV patients
with HCC from those without HCC. At a cut-off value of 0.474,
the sensitivity was 81.6% and the specificity was 83.3% in
discriminating HCC from healthy subjects, and 77.6% sensitivity
and 57.8% specificity in discriminating HBV patients with HCC
from those without HCC at the cut-off value of 0.651. More
importantly, it was found that the levels of miR-122 were
significantly reduced in the post-operative serum samples when
compared to the pre-operative samples, reaching levels compara-
ble with healthy subjects, indicating that the elevation of serum
miR-122 is likely derived from HCC.
MiR-122 not only is evolutionary conserved across species and
but also was identified as the most abundant liver specific miRNA
constituting 70% of total hepatic miRNAs while cloning small
RNAs from different tissues in mice [30,31]. MiR-122 facilitates
replication [32] and translation [33] of hepatitis C viral RNA and
positively regulates cholesterol and triglyceride level [34,35].
Significantly, the down-regulation of miR-122 was detected in
more than 70% of HCC [36]. It was shown that the level of miR-
122 expression increases in the mouse liver throughout develop-
ment, to reach the maximum just before birth. Thus, the loss of
Figure 2. Expression levels of miRNAs in serum of HCC patients, HBV patients without HCC and healthy subjects. Levels of miR-122
(A), miR-222 (B), miR-223 (C) and miR-21 (D) were measured in serum of 48 HCC patients (n=48), HBV patients without HCC (n=48) and healthy
subjects (n=24) by RT-qPCR. Levels of miR-122 were significantly higher in HCC patients than disease controls (p,0.05) or healthy controls
(p,0.001). Although levels of miR-222 and miR-223 were also significantly elevated in HCC patients than in healthy controls (p,0.05), no significant
difference was observed for these two miRNAs between HBV subjects with and without HCC (p.0.05). Levels of miR-21 were reduced in HCC patients
than in healthy controls (p,0.05), no significant difference was observed for miR-21 between HBV subjects with and without HCC (p.0.05).
doi:10.1371/journal.pone.0028486.g002
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differentiation reversion or a block to a less differentiated status of
liver cells. In our study, it appears contrary and unexpected that
the levels of miR-122 are elevated in serum of HCC patients. Our
results showed that the elevated serum miR-122 is presented not
only in HBV patients with HCC but also in HBV patients without
HCC, suggesting that the elevated miR-122 in the serum of
patients may also reflect liver injury [22,37]. Hepatocytes contain
abundant miR-122 and damage of hepatocytes caused by
inflammation due to virus infection or cancer would be expected
to release significant amount of this miRNA into the circulation.
Because serum miRNAs have been shown to be very stable [16],
miRNAs leaked from damaged hepatocytes would accumulate in
blood to a high level. This might explain why miR-122 is down-
regulated in HCC tissues but elevated in serum of HBV patients
without or with HCC. Interestingly, our data indicated that
expression levels of miR-122 in serum were significantly higher in
HCC patients than disease controls or healthy controls, while Xu
et al. showed that expression levels of serum miR-122 were
significantly higher in HBV patients than HCC or healthy controls
[26]. The reason may be that we and Xu et al. use the different
normalization control (miR-16 vs miR-181a and miR-181c).
MiR-223 is one of the miRNAs that has been given much
attention in the literature. This miRNA is usually regarded as a
bone marrow specific miRNA that functions as an important
modulator of cellular differentiation [38,39]. In addition to this, a
recent study observed that miR-223 was commonly repressed in
HCC [11], suggesting a potential role of this miRNA in liver
disease. In our study, levels of miR-223 were significantly elevated
in HCC patients than in healthy controls, while no significant
difference was observed for this miRNA between HBV subjects
with and without HCC. Moreover, the levels of miR-223 in serum
of HBV patients without HCC were higher than those in HCC
patients or healthy subjects. This finding points out that elevated
serum miR-223 could also come from tissue injury such as
hepatitis. Since patients with chronic hepatitis may have more
serious damage of hepatocytes than patients with HCC, it is
reasonable to see much higher level of serum miR-223 in patients
with chronic B hepatitis than in patients with HCC. For example,
similar results have been obtained in the previous study, showing
that elevation of serum miR-223 come from hepatic ischemia/
reperfusion injury [40].
MiR-21 is one of the most prominent miRNAs implicated in the
genesis and progression of human cancer. The earliest study
showed that miR-21 is commonly and markedly up-regulated in
human glioblastoma, and inhibition of miR-21 expression leads to
Figure 4. Receiver operating characteristics (ROC) curve analysis using serum miR-122 for discriminating HCC patients from
healthy controls and HBV patients without HCC. Serum miR-122 yielded an AUC (the areas under the ROC curve) of 0.869 (95% CI: 0.786–0.952)
with 81.6% sensitivity and 83.3% specificity for discriminating HCC patients from healthy controls (A), and an AUC of 0.630 (95% CI: 0.516–0.743) with
77.6% sensitivity and 57.8% specificity for discriminating HBV patients with HCC from those patients without HCC (B).
doi:10.1371/journal.pone.0028486.g004
Figure 3. Expression levels of miR-122 in pre-operative, post-
operative and healthy serum samples. The levels of miR-122 were
significantly reduced in the post-operative serum samples (n=14) when
compared to the pre-operative samples (n=14), reaching levels
comparable with healthy subjects (n=24).
doi:10.1371/journal.pone.0028486.g003
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glioblastoma cell lines [41]. Subsequently, there is a growing body
of evidence to prove that miR-21 is overexpressed in a variety of
tumors such as breast cancer [41], lung cancer [42], colon cancer
[43,44], and HCC [7,8] with proproliferative and anti-apoptotic
function. Recent studies have shown that serum miR-21 levels are
significantly increased in patients with defused large B-cell
lymphoma or ovarian cancer [14,21]. In the present study,
however, we found lower levels of serum miR-21 in HBV patients
without or with HCC than in healthy controls. The role played by
circulating miRNAs is also poorly understood. The detected
circulating miRNAs might be derived from dying tumor cells,
from tumor cells that have been lysed, from cells infiltrating the
lymphomas, from other tissues affected by ongoing diseases, or
because the tumor cells actively secrete miRNAs into the
surrounding environment. These results indicate that miR-21
can act as either oncogene or tumor suppressor, depending on the
targets they regulate and the upstream factors that can regulate
dysfunction of miR-21. Clearly, the exact role of miR-21 in cancer
needs to be fully investigated in the future.
Although the diagnostic efficiency of serum miR-122 may not
be optimal, a panel of serum miRNA markers may improve the
sensitivity and specificity of this assay for HCC screening. Patients
with increased serum miRNAs might prompt more accurate and
specific clinical examinations.
In conclusion, serum miR-122 might serve as a novel and
potential biomarker for detection of HCC in healthy subjects.
Moreover, it might serve as a novel biomarker for liver injury but
not specifically for detection of HCC in chronic HBV infection
patients. Our data serve as basis for further investigation,
preferably in large prospective studies before miR-122 can be
used as a noninvasive screening tool for HCC in routine clinical
practice.
Materials and Methods
Study Design and Patient Samples
This study was divided into four phases: Phase I (Marker
discovery): In this phase, pre-operative sera from 10 HBV-positive
HCC patients were collected from Eastern Hepatobiliary Hospital
(Shanghai, China). Sera from 10 age- and sex-matched healthy
subjects were collected from Changzheng Hospital (Shanghai,
China) as the control. A panel of 10 cancer-associated miRNAs
was chosen on the basis of their reported relevance to HCC [7–12]
(Table 2). By comparing miRNA expression levels from HCC
serum versus normal serum, two differential miRNA expression
patterns were established and then compared. Significantly up- or
down-regulated miRNAs were identified for further analysis in
phase II.
Phase II (Marker selection and validation): Pre-operative sera
from another 48 HBV-positive HCC patients were collected from
Eastern Hepatobiliary Hospital (Shanghai, China). Sera from 48
chronic HBV infection patients without HCC and 24 age- and
sex-matched healthy subjects were collected from Changzheng
Hospital (Shanghai, China) as disease and healthy controls,
respectively. The phase II analysis did not include the data from
phase I. Chronic HBV infection was defined as positivity for HBV
surface antigen for at least 6 months, positivity for HBV DNA by
PCR analysis, and HBV infection-compatible results in a liver
biopsy. An ultrasound scan was performed at baseline to exclude
HCC. Putative miRNAs markers identified in phase I were
verified on these serum from cases and controls.
Phase III: In this phase, sera from another 14 HCC patients
were collected before and 1 month after surgical resection. It is
hypothesized that those up- or down-regulated miRNAs in HCC
should be significantly reduced or elevated after tumor resection.
Phase IV: We examined the correlation between the expressions
of candidate serum miRNAs with clinical parameters of HCC
patients.
The study protocol was approved by the Ethics Committee of
Second Military Medical University and adhered to the tenets of
the Declaration of Helsinki. Additionally, informed consent was
obtained from participants for the use of their blood in this study.
All patients were positive for HBsAg and did not have any other
types of liver diseases such as chronic hepatitis C, alcoholic liver
diseases, autoimmune liver diseases, or metabolic liver diseases.
The diagnosis of HCC was histopathologically confirmed. Data on
all subjects were obtained from medical records, pathology reports
and personal interviews with the subjects. The data collected
include age, gender, serum albumin (ALB) level, total bilirubin
level (T-Bil), alanine aminotransferase (ALT) level, overall survival
and HCC features such as tumor number, size and growth phase.
Clinical stage of HCC was evaluated on the basis of the TNM
classification system. The Child-pugh score allowed to categorize
HCC patients in Child-pugh grades A, B and C.
Serum Preparation and RNA Extraction
The blood was centrifuged at 1600 rpm for 5 min and the
serum aliquoted into 1.7 ml Eppendorf tubes, followed by a
15 min high speed centrifugation at 12000 rpm to completely
remove cell debris, leaving only circulating RNA. For RNA
isolation from serum, 250 ml of serum was homogenized in 750 ml
of Trizol LS (Invitrogen). Then 200 ml of chloroform was added to
the sample and the mixed solution was centrifugated. After an
Table 2. Candidate miRNAs for investigation in the circulation of HCC patients.
miRNAs of interest Previous association with HCC
miR-301, miR-224, miR-221 increased expression in tumorous liver tissues compared with paired adjacent non-tumorous liver tissues from HCC patients
10
miR-21 increased expression in tumorous liver tissues of HCC patients compared with paired adjacent non-tumorous
7 or benign tumorous
8 liver tissues
let-7a increased expression in tumorous liver tissues compared with paired adjacent non-tumorous liver tissues from HCC patients
7
miR-222 increasedexpressionin tumorous liver tissues ofHCC patients compared withpaired adjacent non-tumorous
10 orbenign tumorous
8 liver tissues
miR-122 decreased or increased expression in tumorous liver tissues of HCC patients compared with normal liver
8,9
miR-199a decreased expression in tumorous liver tissues compared with paired adjacent non-tumorous liver tissues from HCC patients
12
miR-223 decreased expression in tumorous liver tissues compared with paired adjacent non-tumorous liver tissues from HCC patients
11
miR-16 reliable endogenous control for investigating serum miRNA levels in recent studies
16
doi:10.1371/journal.pone.0028486.t002
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nol, the pellet was washed twice by centrifugation with 70%
ethanol. The RNA pellet was dried for 10 min at room
temperature and dissolved in 30 ml of diethylpyrocarbonate
(DEPC)-treated water. DNase treatment (Qiagen) was carried
out to remove any contaminating DNA. The concentration and
quality of RNA was measured by UV absorbance at 260 nm and
280 nm (A260/280 ratio) and checked by gel electrophoresis
individually. In general, we obtained 600 ng of RNA from 1 ml of
serum.
Reverse Transcription (RT) and Quantitative PCR (qPCR)
RT and qPCR kits made specifically for accurate miRNA
analysis (Applied Biosystems) were used to evaluate expression of
the chosen miRNAs from serum samples. The 15 mL RT reactions
were performed using a TaqManH microRNA Reverse Tran-
scription Kit (Applied Biosystems, USA) and incubated for 30 min
at 16uC, 30 min at 42uC, 5 min at 85uC, and then maintained at
4uC. For real-time PCR, 1.33 mL diluted RT products were mixed
with 10 mLo f2 6 Taqman PCR master mixture (No AmpErase
UNG), 1 mL TaqMan MicroRNA Assay and 7.67 mL Nuclease-
free water in a final volume of 20 mL according to manufacturer
instructions. All reactions were run on the ABI 7300 (Applied
Biosystems, USA) using the following conditions: 95uC for 10 min,
followed by 40 cycles at 95uC for 15 s, and 60uC for 1 min. Real-
time PCR was done in triplicate, including no-template controls.
Relative expression of miRNA was calculated using the compar-
ative cycle threshold (CT) (2
2DDCT) method [45] with miRNA-16
as the endogenous control to normalize the data. The CT is
defined as the number of cycles required for the FAM signal to
cross the threshold in real-time PCR. DCT was calculated by
subtracting the CT values of miR-16 from the CT values of the
chosen miRNA. DDCT was then calculated by subtracting mean
DCT of the control samples from DCT of tested samples. Fold
change of miRNA was calculated by the equation 2
2DDCT.
Statistical Analysis
Due to the magnitude and range of relative miRNA expression
levels observed, results data were log transformed for analysis.
Data are presented as mean 6 SD. There was no evidence against
normality for the log transformed data as confirmed using the
Kolmogorov-Smirnov test. t-test was used to evaluate expression
differences of the chosen miRNAs between cases and controls.
Receiver operating characteristic (ROC) curves were constructed
and the area under the curve (AUC) was calculated to evaluate the
specificity and sensitivity of predicting cases and controls. All
statistical tests were two-sided, and a probability level of p,0.05
was considered to be statistically significant. Data analysis was
done using SPSS 11.0 software (SPSS, Inc.).
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